Impedimed L-Dex trial gains momentum

Company News

Impedimed Limited (ASX:IPD) says it has secured another NCI designated cancer centre for the post approval trial of its L-Dex device. 
 
The L-Dex technology helps physicians and surgeon detect changes in cellular fluid levels to detect lymphedema post-surgery. 
 
The trial has been gaining momentum with the procedure also recently gaining reimbursement classification. The medical device is also the first of its kind with FDA clearance in the US. 
 
Impedimed reported a net loss of $6.1 million for the full year ending 31 December 2014.

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.